Tecartus® (brexucabtagene autoleucel)
for Leukemia

Tecartus (brexucabtagene autoleucel) is a genetically modified T-cell immunotherapy used to treat adults with mantle cell lymphoma or acute lymphoblastic leukemia. It involves altering a patient's white blood cells to express a specific protein (chimeric antigen receptor–CAR) that helps the immune system identify and attack cancer cells, slowing or stopping their growth.

Heart
Medication Guide Icon Medication Guide
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Leukemia